News
Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...
This was the stock's third consecutive day of gains.
Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...
Zacks Investment Research on MSN1d
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Zacks Investment Research on MSN2d
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key FactsVertex Pharmaceuticals (VRTX) closed the most recent trading day at $452.16, moving +1.56% from the previous trading session. This change outpaced the S&P 500's 0.11% loss on the day. Meanwhile, the ...
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback